Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Clinical trial NCT04671667 · RECRUITING
Trial details
- NCT number
- NCT04671667
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-27
- Primary completion
- 2029-06-30
- Enrollment
- 188
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.